Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Durvalumab for limited stage small-cell lung cancer after
1 therapy
Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2022 View  |  Download
Durvalumab for advanced, EGFR/ALK wild-type, high PD-L1 expression, non-small cell lung cancer- first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Durvalumab and enfortumab vedotin with or without tremelimumab for muscle-invasive bladder cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Enfortumab vedotin (ASG-22ME; Padcev) , Tremelimumab (CP-675206; CP-675 206) Bladder cancer Urological Cancer 2024 View  |  Download
Durvalumab and bevacizumab in addition to transarterial chemoembolisation for locoregional hepatocellular carcinoma Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2021 View  |  Download
Durvalumab adjuvant therapy for treating hepatocellular carcinoma at high risk of recurrence after curative treatment Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Durvalumab add-on therapy for previously untreated locally advanced cervical cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Cervical cancer Female Reproductive Cancer 2022 View  |  Download
Durvalumab (Imfinzi) monotherapy for advanced or metastatic non-small cell lung cancer (EGFR and ALK wild type) – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Durvalumab (Imfinzi) for locally advanced or metastatic urothelial bladder cancer – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2017 View  |  Download
Dupilumab in addition to controller medications for children aged 6 to 11 years with asthma controller medications , Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Asthma Respiratory System 2021 View  |  Download
Dupilumab for treating Prurigo Nodularis Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Prurigo nodularis (PN) Dermatology 2021 View  |  Download
1 2 84 85 86 87 88 117 118
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications